Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (GB:GSK)
LSE:GSK
GlaxoSmithKline (GSK) Share Price & Analysis
508 Followers
GSK Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range1,280.13p - 1,823.50p
Previous Close1,522.5p
Volume490.00K
Average Volume (3M)7.61M
Market Cap
£62.09B
Enterprise Value74.37B
Total Cash (Recent Filing)£5.18B
Total Debt (Recent Filing)£18.02B
Price to Earnings (P/E)13.8
Beta0.49
Next Earnings
Jul 31, 2024EPS Estimate
£0.38Last Dividend Ex-Date
May 16, 2024Dividend Yield3.88%
Share Statistics
EPS (TTM)1.10
Shares Outstanding4,117,033,438
10 Day Avg. Volume11,123,383
30 Day Avg. Volume7,609,178
Standard Deviation0.05
R-Squared0.29
Alpha0.00638
Financial Highlights & Ratios
Price to Book (P/B)-8.00
Price to Sales (P/S)242.10
Price to Cash Flow (P/CF)6.10
P/FCF Ratio7.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
1,836.09pPrice Target Upside20.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
GlaxoSmithKline News
PremiumCompany Announcements
GSK’s Blenrep Sets Sights on Transforming Myeloma Treatment
PremiumCompany Announcements
GSK Executives Invest in Company Shares
PremiumCompany Announcements
GSK Executives Reinforce Commitment via Share Investment
PremiumCompany Announcements
GSK Executives Boost Shareholdings Through Dividends
PremiumCompany Announcements
GSK Leaders Invest in Company’s FutureBulls Say, Bears Say
Bulls Say
Earnings PerformanceRecent earnings momentum has been strong and is expected to continue driven by Arexvy and Shingrix.
Product ExpansionJemperli expansion opportunities into various cancer treatments, potentially tripling the addressable patient pool.
Stock RecommendationAnalyst recommends the stock due to an expected share price return of 25.8%.
Bears Say
Competitive ThreatsIncreasing competition, particularly from Moderna, poses a risk to Arexvy's sales estimates.
Legal RisksRisk of inherently unpredictable jury trials awarding substantial damages unless it successfully appeals or settles.
Regulatory DecisionsThe US Delaware District Court judge overseeing approximately 73,000 GSK Zantac cancer claims ruled that the claims can move to trial.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.28% Insiders
11.75% Mutual Funds
10.66% Other Institutional Investors
76.31% Public Companies and Individual Investors
GSK FAQ
What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest share price was 1280.13p and its highest was 1823.50p in the past 12 months.
What is GlaxoSmithKline’s market cap?
Currently, no data Available
When is GlaxoSmithKline’s upcoming earnings report date?
GlaxoSmithKline’s upcoming earnings report date is Jul 31, 2024 which is in 9 days.
How were GlaxoSmithKline’s earnings last quarter?
GlaxoSmithKline released its earnings results on May 01, 2024. The company reported 0.431p earnings per share for the quarter, beating the consensus estimate of 0.367p by 0.064p.
Is GlaxoSmithKline overvalued?
According to Wall Street analysts GlaxoSmithKline’s price is currently Undervalued.
Does GlaxoSmithKline pay dividends?
GlaxoSmithKline pays a Annually dividend of 15p which represents an annual dividend yield of 3.88%. See more information on GlaxoSmithKline dividends here
What is GlaxoSmithKline’s EPS estimate?
GlaxoSmithKline’s EPS estimate is £0.38.
How many shares outstanding does GlaxoSmithKline have?
GlaxoSmithKline has 4,145,044,000 shares outstanding.
What happened to GlaxoSmithKline’s price movement after its last earnings report?
GlaxoSmithKline reported an EPS of 0.431p in its last earnings report, beating expectations of 0.367p. Following the earnings report the stock price went up 1.913%.
Which hedge fund is a major shareholder of GlaxoSmithKline?
Currently, no hedge funds are holding shares in GB:GSK
---
GlaxoSmithKline Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
1,836.09p (20.76% Upside)
1,836.09p (20.76% Upside)
Insider Transactions
Bought Shares
Worth £76.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
16.29%
12-Months-Change
Fundamentals
Return on Equity
34.95%
Trailing 12-Months
Asset Growth
-0.14%
Trailing 12-Months
Company Description
GlaxoSmithKline
In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, oncology, and antiviral, as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products.
---
GSK Stock 12 Month Forecast
Average Price Target
1,836.09p
▲(20.76% Upside)
Technical Analysis
Best Analysts Covering GSK
1 Year
1 Year Success Rate
22/35 ratings generated profit
1 Year Average Return
+5.06%
reiterated a buy rating 13 days ago
Copying Emmanuel Papadakis's trades and holding each position for 1 Year would result in 62.86% of your transactions generating a profit, with an average return of +5.06% per trade.
---